BBS10 related diagnostic methods for Bardet-Biedl syndrome
View Patent ↗The present invention relates to the identification of a gene, designated BBS1O, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. Methods of use for the gene, for example in diagnosis and therapy of BBS, also are described.
1. A method for determining whether a subject has or is likely to develop Bardet-Biedl Syndrome (BBS), comprising the steps of:
providing a biological sample of a subject; and
determining whether the sample comprises a nucleotide sequence encoding a variant BBS10 polypeptide sequence, wherein the variant BBS10 polypeptide sequence has an amino acid sequence that differs from the sequence set forth in SEQ ID NO: 2 by one or more mutations selected from the group consisting of R34P, R49W, C91W, L170S, C195W, Y197C, F199Del, V240G, L308F, S311A, S329L, P363L, L414S, K579R, Y613H, Y613C, G677V, T689P, A13fs, S73fs, C91fs, V230fs, Q242fs, K243fs, F275fs, S303fs, Y321X, L348fs, L367fs, A474fs, T483fs, T514fs, Y559fs, and V707fs
wherein the presence of a nucleotide sequence that encodes the variant BBS10 polypeptide sequence indicates that the subject has or is likely to develop BBS.
2. The method of claim 1 , further comprising: determining whether the sample comprises a second nucleotide sequence encoding second variant BBS10 polypeptide sequence, wherein the second variant BBS10 polypeptide sequence has an amino acid sequence that differs from the sequence set forth in SEQ ID NO: 2 by one or more mutations selected from the group consisting of R34P, R49W, C91W, LI70S, C195W, YI97C, F199De1, V240G, L308F, S311A, S329L, P363L, L414S, K579R, Y613H, Y613C, G677V, T689P, A13fs, S73fs, C91fs, V230fs, Q242fs, K243fs, F275fs, S303fs, Y321X, L348fs, L367fs, A474fs, T483fs, T514fs, Y559fs, and V707fs.
3. The method of claim 1 , wherein the biological sample is a sample selected from the group consisting of a tissue sample, a blood sample, a semen sample and a germ cell sample.
4. The method of claim 1 , wherein the subject is a human adult, a human child, a human fetus, a human embryo or a human fertilized cell.
5. The method of claim 1 , wherein the determining step is performed by sequencing the BBS10 nucleic acid.
6. The method of claim 1 , wherein the determining step is performed by hybridizing a nucleic acid probe to the BBS10 nucleic acid or an amplification product thereof.